Intech Biopharm Stock Revenue
| 6461 Stock | TWD 28.00 0.65 2.27% |
Intech Biopharm fundamentals help investors to digest information that contributes to Intech Biopharm's financial success or failures. It also enables traders to predict the movement of Intech Stock. The fundamental analysis module provides a way to measure Intech Biopharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intech Biopharm stock.
Intech |
Intech Biopharm Company Revenue Analysis
Intech Biopharm's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Intech Biopharm Revenue | 38.9 M |
Most of Intech Biopharm's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intech Biopharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Intech Biopharm reported 38.9 M of revenue. This is 99.49% lower than that of the Healthcare sector and 94.76% lower than that of the Biotechnology industry. The revenue for all Taiwan stocks is 99.59% higher than that of the company.
Intech Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intech Biopharm's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intech Biopharm could also be used in its relative valuation, which is a method of valuing Intech Biopharm by comparing valuation metrics of similar companies.Intech Biopharm is currently under evaluation in revenue category among its peers.
Intech Fundamentals
| Return On Equity | -0.28 | |||
| Return On Asset | -0.0739 | |||
| Operating Margin | (9.09) % | |||
| Current Valuation | 5.09 B | |||
| Shares Outstanding | 116.96 M | |||
| Shares Owned By Insiders | 47.02 % | |||
| Shares Owned By Institutions | 6.26 % | |||
| Price To Book | 3.67 X | |||
| Price To Sales | 128.48 X | |||
| Revenue | 38.9 M | |||
| Gross Profit | (119.37 M) | |||
| EBITDA | (196.92 M) | |||
| Net Income | (301.76 M) | |||
| Total Debt | 940.77 M | |||
| Book Value Per Share | 9.61 X | |||
| Cash Flow From Operations | (200.61 M) | |||
| Earnings Per Share | (2.87) X | |||
| Number Of Employees | 87 | |||
| Beta | 0.59 | |||
| Market Capitalization | 3.71 B | |||
| Total Asset | 2.6 B | |||
| Z Score | 1.8 | |||
| Net Asset | 2.6 B |
About Intech Biopharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intech Biopharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intech Biopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intech Biopharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Intech Biopharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Intech Biopharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Intech Biopharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Intech Stock
| 0.84 | 4743 | Oneness Biotech | PairCorr |
| 0.86 | 6547 | Medigen Vaccine Biologics | PairCorr |
| 0.81 | 4174 | OBI Pharma | PairCorr |
Moving against Intech Stock
| 0.72 | 1449 | Chia Her Industrial Split | PairCorr |
| 0.7 | 2609 | Yang Ming Marine | PairCorr |
| 0.62 | 4162 | PharmaEngine | PairCorr |
| 0.53 | 0050 | YuantaP shares Taiwan | PairCorr |
| 0.46 | 0057 | Fubon MSCI Taiwan | PairCorr |
The ability to find closely correlated positions to Intech Biopharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Intech Biopharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Intech Biopharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Intech Biopharm to buy it.
The correlation of Intech Biopharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Intech Biopharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Intech Biopharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Intech Biopharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Intech Stock Analysis
When running Intech Biopharm's price analysis, check to measure Intech Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intech Biopharm is operating at the current time. Most of Intech Biopharm's value examination focuses on studying past and present price action to predict the probability of Intech Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intech Biopharm's price. Additionally, you may evaluate how the addition of Intech Biopharm to your portfolios can decrease your overall portfolio volatility.